Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Oncol Pharm Pract ; 28(1): 247-249, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34233543

RESUMEN

INTRODUCTION: Capecitabine is an antimetabolite antineoplastic agent widely used in the treatment gastrointestinal cancers. The common frequently reported cutaneous adverse drug reaction associated with capecitabin are a palmar-plantar erythrodysesthesia syndrome, rash and hyperpigmentation. This case reports a capecitabine-induced palmar hypopigmentation. CASE REPORT: We report the case of a 74-years old patient with jejunum adenocarcinoma treated by capecitabine. The patient developed a pseudo-vitiligo after 2 cycles capecitabine and without history of cutaneous disorders. The skin lesions were characterized with skin hypopigmentation on both hands.Management and outcome: The hypopigmentation slowly recovered after capecitabine discontinuation. CONCLUSION: This is the first described case of pseudo-vitiligo induced by capecitabine. This impressive but non-severe adverse effect should be known by oncologists and oncology pharmacists to reassure the patients in particular about the possible recovery after discontinuation of capecitabine.


Asunto(s)
Adenocarcinoma , Neoplasias Gastrointestinales , Hipopigmentación , Adenocarcinoma/tratamiento farmacológico , Anciano , Antimetabolitos Antineoplásicos/efectos adversos , Capecitabina/efectos adversos , Fluorouracilo/efectos adversos , Neoplasias Gastrointestinales/tratamiento farmacológico , Humanos , Hipopigmentación/inducido químicamente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...